ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1906

Using Multi-modal Ultrasound to Assess Disease Activity Within the Salivary Glands of Patients with Primary Sjögren’s Syndrome Treated with Ianalumab (VAY736)

Torsten Diekhoff 1, Maximilian Posch 2, Frank Wagner 2, Thomas Fischer 1, Quirino Schefer 2, Thomas Dörner 3, Didier Laurent 4, Yue Li 4 and Stephen Oliver4, 1Charité University Hospital, Berlin, Germany, 2Charité Research Organisation, Berlin, Germany, 3Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, 4Novartis Pharma AG, Basel, Switzerland

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: B cell targeting, randomized trials and salivary gland, Sjogren's syndrome, ultrasonography

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Session Title: 4M119: Sjögrenʼs Syndrome – Basic & Clinical Science (1902–1907)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: To use ultrasound (US) to demonstrate that ianalumab, a monoclonal antibody with dual mechanisms-of-action of BAFF:BAFF-R blockade and enhanced, ADCC-mediated B cell depletion, can modulate the inflammation and morphology within salivary glands of patients with primary Sjögren’s syndrome (pSS).

Methods: In a single-center study, 27 patients fulfilling the revised American European consensus criteria for pSS with stimulated whole salivary flow rate of >0 mL/minute and active disease (EULAR Sjögren’s Syndrome Disease Activity Index; ESSDAI ≥6) were randomly assigned between three treatment groups in a 24-week double-blind treatment period to receive a single i.v. dose of either 3 mg/kg or 10 mg/kg ianalumab, or placebo1. Concurrent with clinical and laboratory outcomes that included ESSDAI, Physician’s Global Assessment, and patient-reported outcomes for disease activity, fatigue and quality of life ( EULAR Sjögren’s Syndrome Patient Response Index, Multi-Dimensional Fatigue Index, Short Form-36, Patient’s Global Assessment), multi-modal US images were acquired at baseline and weeks 6, 12, and 24. Using a single US device, applied modalities included: 1) echostructure by B-mode scored 0-4 in 5 categories according to de Vita classification2,3,  2) large vessel blood flow by power Doppler (vascularity index, scored 0 for no vascularization and 1-3 for mild, moderate and high vascularization, respectively), and, limited to parotid glands (PG) only, 3) microvascularization using contrast-enhanced US (area under the curve, time to peak) and 4) gland stiffness by sonoelastography4,5.

Results: The overall profiles of US data differed greatly between PG and submandibular glands (SMG) but were comparable between the respective left and right sides of these glands. A numerical improvement in both PG and SMG quality and declining inflammation in the glands were observed, including more de Vita responders (patients achieving ≥1 point reduction from baseline) in the VAY736 groups than in placebo (Figure 1), and changes in perfusion of both PG and SMG, as shown from large vessels and microvascular assessments (Figure 2), and a trend of decrease in PG stiffness (Figure 2). Change in some US parameters is observed to have correlation with some clinical endpoints, including change in thickness with change in ESSDAI at week 12 (Spearman correlation coefficient = -0.63, p value = 0.0031), and change in TTP at week 12 correlated with change in patient global assessment (Spearmann cc=0.61; p=0.018) and with MFI-physical fatigue (Spearman cc = 0.61, p-value = 0.046).

Conclusion: Early signs of salivary gland improvement in response to an effective intervention can be shown using non-invasive, comprehensive, ultrasound-based approach at multiple time points without the need of biopsies.

Figure 1. Proportions of de Vita responder by treatment group, week and gland type are shown in barchart. The responder is defined as one point reduction from baseline in de Vita score. The numbers on top of the bars, “m/n”, indicates m responders out of n patients in a given group.

Figure 2. Change from baseline in a few ultrasound parameters are presented in boxplots by group over time, overlaid with individual data points. Median values are shown as the middle line within the boxes and mean values are indicated by diamonds. The direction of disease improvement is indicated by the arrow along the y axis. Two extreme data points greater than 70 are left out in the boxplot for the parameter of time-to-peak.


Disclosure: T. Diekhoff, None; M. Posch, Charité Research Organisation, 3; F. Wagner, Charité Research Organisation, 3; T. Fischer, None; Q. Schefer, Charité Research Organisation, 3; T. Dörner, AbbVie, 5, Celgene, 5, Eli Lilly and Company, 5, 8, GSK, 2, Janssen, 2, 5, Novartis, 2, 5, Novartis Pharma AG, 5, Roche, 5, 8, Samsung, 5, 8, Sanofi, 2, UCB, 5, UCB Pharma, 2, 5; D. Laurent, Novartis Pharma AG, 1, 3; Y. Li, Novartis Pharma AG, 1, 3; S. Oliver, Novartis Pharma AG, 1, 3.

To cite this abstract in AMA style:

Diekhoff T, Posch M, Wagner F, Fischer T, Schefer Q, Dörner T, Laurent D, Li Y, Oliver S. Using Multi-modal Ultrasound to Assess Disease Activity Within the Salivary Glands of Patients with Primary Sjögren’s Syndrome Treated with Ianalumab (VAY736) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/using-multi-modal-ultrasound-to-assess-disease-activity-within-the-salivary-glands-of-patients-with-primary-sjogrens-syndrome-treated-with-ianalumab-vay736/. Accessed May 16, 2022.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/using-multi-modal-ultrasound-to-assess-disease-activity-within-the-salivary-glands-of-patients-with-primary-sjogrens-syndrome-treated-with-ianalumab-vay736/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.